Stock listing

gettex:AP82 Aptevo Therapeutics Inc. Aktie

German listing (gettex) of Aptevo Therapeutics Inc. · home listing NASDAQ:APVO

Follow Aptevo Therapeutics Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:APVO

$0.404 USD -0.042 (-9.4%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:APVO

Past year -97.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.394 – $0.425 USDNov 20, 2026
Volume
148,733 sharesNov 20, 2026
Market cap
$1.40M USDAt the close on Nov 20, 2026 · price × 3.46M shares outstanding
52-week range
$0.394 – $25.560 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$194,871 USDMedian day 42,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Aptevo Therapeutics Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:APVO · Home$0.404 USD-0.042 (-9.4%)148,733$0.415$0.425$0.394$0.446Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:APVO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.404-0.042-9.4%$0.415$0.425$0.394148,733
$0.446-0.015-3.3%$0.470$0.470$0.422627,299
$0.461-0.088-16.0%$0.540$0.550$0.450138,059
$0.549-0.045-7.7%$0.600$0.606$0.546163,744
$0.594-0.066-10.0%$0.665$0.670$0.594109,554
$0.660-0.100-13.1%$0.770$0.770$0.650227,148
$0.760-0.320-29.6%$0.787$0.830$0.740610,953
$1.080-0.050-4.4%$1.140$1.140$1.07050,530
$1.130-0.110-8.9%$1.190$1.220$1.09074,299
$1.240-0.030-2.4%$1.300$1.323$1.20032,800
$1.270-0.100-7.3%$1.370$1.370$1.070144,100
$1.370+0.010+0.7%$1.345$1.380$1.31014,800
$1.360+0.010+0.7%$1.440$1.440$1.31014,000
$1.350+0.010+0.7%$1.393$1.398$1.32923,000
$1.340-0.020-1.5%$1.360$1.386$1.31028,700
$1.360+0.060+4.6%$1.320$1.410$1.31058,500
$1.300+0.020+1.6%$1.360$1.370$1.26042,200
$1.280-0.220-14.7%$1.550$1.580$1.25380,600
$1.500-0.110-6.8%$1.740$1.740$1.430123,700
$1.6100.0000.0%$1.610$1.636$1.6007,200
$1.610+0.010+0.6%$1.605$1.640$1.6005,300
$1.600-0.015-0.9%$1.630$1.650$1.6008,600
$1.615+0.015+0.9%$1.600$1.650$1.60012,600
$1.600-0.020-1.2%$1.655$1.655$1.5688,400
$1.620-0.080-4.7%$1.730$1.730$1.60031,100
$1.700-0.030-1.7%$1.730$1.740$1.70010,800
$1.7300.0000.0%$1.730$1.780$1.71021,900
$1.730-0.106-5.8%$1.790$1.790$1.70085,700
$1.836+0.046+2.6%$1.790$1.970$1.760282,300
$1.790-0.010-0.6%$1.790$1.810$1.7806,700
$1.800-0.040-2.2%$1.770$1.840$1.77026,700
$1.840+0.045+2.5%$1.760$1.850$1.76012,100
$1.795-0.005-0.3%$1.820$1.920$1.79035,400
$1.800+0.040+2.3%$1.760$1.850$1.75028,100
$1.7600.0000.0%$1.800$1.800$1.76012,600
$1.760-0.060-3.3%$1.820$1.840$1.75025,000
$1.820-0.040-2.2%$1.840$1.900$1.81024,100
$1.860-0.050-2.6%$1.900$1.910$1.84015,000
$1.910+0.020+1.1%$1.860$1.980$1.86047,000
$1.890+0.060+3.3%$1.830$1.900$1.81825,500
$1.830-0.060-3.2%$1.880$1.900$1.81033,000
$1.890+0.040+2.2%$1.880$1.895$1.80053,300
$1.850+0.040+2.2%$1.814$1.890$1.81439,200
$1.810-0.030-1.6%$1.842$1.890$1.80522,400
$1.8400.0000.0%$1.850$1.890$1.82040,800
$1.840+0.120+7.0%$1.790$1.900$1.730423,800
$1.720+0.010+0.6%$1.711$1.800$1.71154,000
$1.710-0.090-5.0%$1.810$1.840$1.71048,300
$1.800-0.020-1.1%$1.854$1.895$1.80046,100
$1.820-0.010-0.5%$1.830$1.920$1.80043,600
$1.830-0.015-0.8%$1.820$1.880$1.76056,500
$1.845-0.035-1.9%$1.890$1.990$1.82043,900
$1.880+0.140+8.0%$1.770$1.930$1.745168,100
$1.740+0.030+1.8%$1.740$1.796$1.640272,100
$1.710-0.890-34.2%$2.110$2.180$1.3701,689,600
$2.600+0.260+11.1%$2.340$2.770$2.3301,027,600
$2.340-0.100-4.1%$2.440$2.440$2.34032,000
$2.440+0.075+3.2%$2.350$2.450$2.35029,700
$2.365-0.055-2.3%$2.460$2.460$2.31021,500
$2.420+0.010+0.4%$2.410$2.420$2.34035,100
$2.410-0.050-2.0%$2.490$2.550$2.41027,600
$2.460+0.050+2.1%$2.370$2.500$2.30158,598
$2.410-0.270-10.1%$2.760$2.760$2.380194,986
$2.680-0.080-2.9%$2.840$2.850$2.58054,100
$2.760+0.030+1.1%$2.740$2.912$2.72363,800

Splits

5 splits since 2020 · NASDAQ:APVO · every price before a split is adjusted for it

DayRatioWhat
1-for-18Consolidation
1-for-20Consolidation
1-for-37Consolidation
1-for-44Consolidation
1-for-14Consolidation
Ticker
gettex:AP82
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
gettex
Currency
EUR

What changed lately

Latest news

All Aptevo Therapeutics Inc. news

Aptevo Therapeutics Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
22 in the last 12 months · 101 in all · newest Nov 16, 2026 · oldest 2019
Decks
10 decks · latest Mar 20, 2025

Where Aptevo Therapeutics Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:APVO · Home listingNASDAQUnited StatesUSD
BOATS:APVOBOATSUnited StatesUSD
gettex:AP82 · This pagegettexGermanyEUR
Frankfurt:AP82FrankfurtGermanyEUR
Munich:AP82MunichGermanyEUR

Valuation

Price/book 0.4× against a median of 0.2×: 6th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$2.88M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
1.0×
Beta vs S&P 500
0.93

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Aptevo Therapeutics Inc. · NASDAQ:APVOUS$1.40M−US$2.88Mn/an/an/a0.4×n/a1.0×0.93
PRF Technologies Ltd. · NASDAQ:PRFXUS$1.66M−US$9.82Mn/a−249×n/a0.1×n/a0.0×1.93
Jupiter Neurosciences, Inc. · NASDAQ:JUNSUS$1.63MUS$1.33Mn/a16.9×n/an/an/an/a1.88
Kairos Pharma, Ltd. · AMEX:KAPAUS$1.48M−US$1.65Mn/an/an/a0.4×n/a0.0×1.36
BioRestorative Therapies, Inc. · NASDAQ:BRTXUS$1.45M−US$2.11Mn/a−5.9×n/a0.5×n/a0.0×1.81
Nutra Pharma Corp. · OTC:NPHCUS$1.43MUS$13.99Mn/a87.0×n/an/an/an/an/a
Agentix Corp. · OTC:AGTXUS$1.35MUS$1.34Mn/an/an/an/an/an/a-0.73
Clearmind Medicine Inc. · NASDAQ:CMNDUS$1.33M−US$9.01Mn/an/an/a0.2×n/a0.0×0.29
Artelo Biosciences, Inc. · NASDAQ:ARTLUS$1.30MUS$1.34Mn/an/an/a0.2×n/a0.0×1.36
International Stem Cell Corporation · OTC:ISCOUS$1.28M−US$18.76M0.1×−2.0×n/a0.1×222.6%0.0×-0.52
SureNano Science Ltd · CSE:SUREUS$1.17MUS$672,274n/an/an/a0.3×n/a0.0×0.25
Median of the othersUS$1.39M−US$488,5190.1×−2.0×0.2×222.6%0.0×1.36

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
25.50 USD · Analysts' mean
EPS, year to Dec 2026
-16.02 · 1 analyst

Team and board

Officers

OfficerRole
Jeff LamothePresident and Chief Executive Officer
Daphne TaylorSenior Vice President and Chief Financial Officer
Daniel J. Abdun-NabiPresident
SoYoung KwonSenior Vice President and General Counsel, Business Development and Corporate Affairs
Miriam Weber MillerVice President, Investor Relations and Corporate Communications
Dirk HuebnerSenior Vice President and Chief Medical Officer
Mary J. JanatpourSenior Vice President and Chief Scientific Officer
Marvin L. WhiteExecutive Chair

Board

DirectorRole
Marvin L. WhiteExecutive Chair
Jeff LamothePresident and Chief Executive Officer
John E. NiederhuberLead Independent Director
Zsolt HarsanyiDirector

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026 · Before open−7.7%
Q2 2026Aug 14, 2026 · Before open−13.5%
Q1 2026May 13, 2026 · After close+0.7%
Q4 2025Mar 26, 2026−3.5%
Q3 2025Nov 6, 2025 · After close0.0%
Q2 2025Aug 11, 2025 · Before open−4.9%
Q1 2025May 15, 2025 · After close−3.0%
Q4 2024Feb 14, 2025 · Before open−8.2%
Q3 2024Nov 7, 2024 · Before open+19.8%
Q2 2024Aug 8, 2024 · Before open+0.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · Before open−11.6%
Q4 2023Mar 5, 2024 · Before open−8.6%
Q3 2023Nov 14, 2023 · Before open+6.8%
Q2 2023Aug 10, 2023 · Before open−9.7%
Q1 2023May 11, 2023 · Before open−2.3%
Q4 2022Mar 30, 2023 · Before open+1.0%
Q3 2022Nov 10, 2022 · Before open+2.5%
Q2 2022Aug 11, 2022 · Before open−1.8%
Q1 2022May 12, 2022 · Before open+11.3%
Q4 2021Mar 24, 2022 · Before open+32.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (March 2025)Investor deck27 slidesMar 20, 2025
Investor Presentation (February 2025)Investor deck30 slidesFeb 11, 2025
Investor Presentation (January 2019)Investor deck31 slidesJan 9, 2019
Investor Presentation (January 2018)Investor deck38 slidesJan 8, 2018
Investor Presentation (November 2017)Investor deck38 slidesNov 9, 2017
Investor Presentation (November 2017)Investor deck30 slidesNov 2, 2017
BIO International Convention 2017Conference53 slidesJun 20, 2017
Investor Presentation (January 2017)Investor deck30 slidesJan 9, 2017
Investor Presentation (November 2016)Investor deck30 slidesNov 28, 2016
Investor Presentation (August 2016)Investor deck28 slidesAug 8, 2016

Open Decks

Financings

RaiseDate
Warrant exercise of common stock on exercise of existing warrants
Closed: US$3M raised · US$1.08 a share · Warrants at US$1.08 for 60 months · Roth Capital Partners
Dealers: Roth Capital Partners
Use of proceeds: Working capital purposes
Nov 12, 2026
Common stock on exercise of existing warrants
Closed: US$4.03 a share · Warrants at US$4.03 for 60 months · Roth Capital Partners, LLC
Dealers: Roth Capital Partners, LLC (lead)
Use of proceeds: Working capital
Aug 13, 2026
Private placement of unregistered shares of common stock (or pre-funded warrants) with common warrants
Closed: US$4.03 a share · Warrants at US$4.03 for 60 months · Roth Capital Partners, LLC
Dealers: Roth Capital Partners, LLC (lead)
Use of proceeds: Working capital
Aug 13, 2026
Shares under equity line of credit
Announced: raise
Buyers: Yorkville Advisors Global, LP (counterparty to $60 million equity line of credit; Aptevo may sell shares to it from time to time)
Use of proceeds: Support ongoing clinical development, advance preclinical programs and fund general corporate purposes
Jan 9, 2026
Registered direct offering of common stock or pre-funded warrants and common warrants
Closed: US$8M raised · US$3.25 a share · Warrants at US$3.25 for 60 months · Roth Capital Partners
Dealers: Roth Capital Partners (lead)
Use of proceeds: Continued clinical development of product candidates, working capital and general corporate purposes
Jun 20, 2025
Registered direct offering of common stock
Closed: US$2M raised · US$0.862 a share · Roth Capital Partners
Dealers: Roth Capital Partners (lead)
Use of proceeds: Continued clinical development of product candidates, working capital and general corporate purposes
Apr 22, 2025
Registered direct offering of common stock and warrants in concurrent private placement
Closed: US$2.1M raised · US$1.19 a share · Warrants at US$1.19 for 60 months · Roth Capital Partners
Dealers: Roth Capital Partners (lead)
Use of proceeds: Continued clinical development of product candidates, working capital and general corporate purposes
Apr 4, 2025
Warrant exercise of common stock upon exercise of existing warrants
Announced: about US$6.2M · US$7.5 a share · Warrants at US$9.53 for 60 months · Roth Capital Partners
Dealers: Roth Capital Partners
Use of proceeds: Working capital and general corporate purposes
Dec 12, 2024

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0003.11M12.3M4.31M32.4M23.1M14.7M9.98M
Cost of revenue240.0K352.0K17.1M17.9M19.0M17.9M19.9M11.2M5.01M12.5M
Gross profit-240.0K-352.0K-567.0K3.11M12.3M-13.5M-2.23M11.9M9.65M12.3M
Research and development14.5M14.4M17.1M17.9M19.0M17.9M24.8M35.4M29.0M29.1M
Selling, general and administrative11.8M10.2M11.8M13.9M14.7M14.0M25.3M28.1M34.6M36.2M
Operating income-26.3M-24.6M-28.9M-28.6M-21.4M-27.5M-41.0M-51.7M-53.9M-138.8M
Depreciation and amortization240.0K352.0K567.0K901.0K1.14M1.41M2.23M2.39M3.13M3.36M
EBITDA-26.1M-24.3M-28.3M-27.7M-20.3M-26.1M-38.7M-49.3M-50.8M-135.4M
Interest expense35.7M7.06M00000
Income before tax-26.0M-24.1M-18.6M7.01M-29.4M-30.9M-43.1M-53.7M-55.9M-139.6M
Income tax0-1.24M-35.7M-2.10M-12.5M-2.62M-23.3M-23.3M-19.7M
Net income-26.0M-24.1M-17.4M8.03M-28.5M-17.8M-40.4M-53.7M6.97M-112.4M
Earnings per share, basic-87.27-31,460.23-2,316.831.57-6.07-5.23-13.86-2.390.33-5.55
Earnings per share, diluted-87.27-31,460.23-2,316.831.57-6.07-5.23-13.86-2.390.33-5.55

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents21.6M8.71M16.9M22.6M45.0M40.0M12.4M30.6M7.09M9.68M
Short-term investments73.7M73.7M44.8M
Receivables2.50M3.66M2.37M7.02M5.22M2.14M307.0K
Inventory1.57M3.08M4.78M6.14M1.78M1.03M461.0K
Current assets23.1M10.7M19.1M27.4M52.6M47.3M30.0M48.7M95.1M71.4M
Property, plant and equipment303.0K543.0K895.0K1.46M2.38M2.81M3.95M5.20M5.84M5.91M
Goodwill00
Total assets27.2M15.6M24.8M34.2M56.6M53.5M53.4M67.5M117.0M91.9M
Accounts payable877.0K1.24M3.98M3.50M3.46M5.58M6.43M11.7M7.35M10.5M
Current liabilities6.05M6.21M7.22M8.71M34.8M14.5M38.2M17.6M18.5M19.5M
Long-term debt1.46M3.71M20.1M19.3M15.7M18.4M
Total debt4.63M4.63M04.01M16.0M28.2M19.9M19.3M19.1M18.4M
Total liabilities9.81M10.8M12.6M16.2M55.4M37.0M41.6M37.1M35.0M41.3M
Shareholders' equity17.4M4.75M12.2M18.0M1.22M16.6M11.8M30.4M82.0M50.6M
Shares outstanding997.8K4.05K12.0K6.47M4.90M4.41M3.23M22.8M21.6M20.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-25.6M-23.8M-11.7M-21.0M-21.7M-29.3M-42.4M-51.4M-41.6M-36.9M
Capital spending000-29.0K-713.0K-88.0K-153.0K-976.0K-1.40M-2.51M
Free cash flow-25.6M-23.8M-11.7M-21.1M-22.4M-29.4M-42.5M-52.4M-43.0M-39.4M
Cash from investing000-29.0K-713.0K28.0M4.10M72.8M29.5M-47.4M
Cash from financing38.5M15.6M6.00M-2.62M26.2M23.9M20.1M-787.0K19.5M89.3M
Dividends paid-1.57M-4.00K-10.2M-21.2M-58.0K00
Share buybacks-10.0K-4.00K10.2M-11.0K-58.0K-758.0K-758.0K38.0K
Change in cash12.9M-8.19M-5.73M-23.7M3.77M22.6M-18.1M20.6M7.42M5.04M

Open Financials

Filings

FilingDateTypeFiled with
S-1 · Registration statementNov 20, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportNov 16, 2026ResultsSEC
PRE 14A · Preliminary proxy statementNov 13, 2026Meeting noticeSEC
8-K · Current reportNov 12, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2026Big-stake noticeSEC
8-K · Current reportNov 9, 2026Current reportSEC
8-K · Current reportNov 5, 2026Current reportSEC
8-K · Current reportOct 30, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
424B5 · ProspectusOct 30, 2026Offer documentSEC
8-K · Current reportOct 26, 2026Current reportSEC
8-K · Current reportOct 23, 2026Material contractSEC
8-K · Current reportOct 14, 2026Current reportSEC
S-8 · Registration statement for employee plansSep 25, 2026Offer documentSEC
8-K · Current reportSep 24, 2026Current reportSEC
8-K · Current reportSep 23, 2026Meeting outcomeSEC
424B4 · ProspectusSep 3, 2026Offer documentSEC
8-K · Current reportSep 3, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveSep 3, 2026Other filingsSEC
DEF 14A · Proxy statementAug 31, 2026Meeting noticeSEC
CORRESP · Letter to the SECAug 31, 2026Other filingsSEC
UPLOAD · Letter from the SECAug 27, 2026Other filingsSEC
DAug 26, 2026Other filingsSEC
PRE 14A · Preliminary proxy statementAug 21, 2026Meeting noticeSEC
S-1 · Registration statementAug 21, 2026Offer documentSEC
8-K · Current reportAug 21, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 14, 2026ResultsSEC
8-K · Current reportAug 13, 2026Material contractSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
DEF 14A · Proxy statementJul 31, 2026Meeting noticeSEC
ARS · Annual report to shareholdersJul 31, 2026Annual reportSEC
8-K · Current reportJul 27, 2026Current reportSEC
S-8 · Registration statement for employee plansJul 24, 2026Offer documentSEC
8-K · Current reportJun 30, 2026Material contractSEC
SCHEDULE 13G · Big-stake noticeJun 22, 2026Big-stake noticeSEC
3 · Initial statement of ownershipJun 22, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 28, 2026Insider tradeSEC
8-K · Current reportMay 27, 2026Material contractSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 13, 2026ResultsSEC
8-K · Current reportMay 6, 2026Current reportSEC
10-K · Annual reportMar 26, 2026Annual reportSEC
8-K · Current reportMar 26, 2026ResultsSEC
8-K · Current reportMar 10, 2026Current reportSEC
8-K · Current reportFeb 18, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
8-K · Current reportFeb 3, 2026Management or board changeSEC
EFFECT · Notice that a registration is effectiveFeb 2, 2026Other filingsSEC
424B4 · ProspectusJan 30, 2026Offer documentSEC
CORRESP · Letter to the SECJan 29, 2026Other filingsSEC
UPLOAD · Letter from the SECJan 29, 2026Other filingsSEC
S-1 · Registration statementJan 28, 2026Offer documentSEC
DEF 14A · Proxy statementJan 26, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementJan 16, 2026Meeting noticeSEC
8-K · Current reportJan 9, 2026Material contractSEC
8-K · Current reportDec 29, 2025Current reportSEC
8-K · Current reportDec 9, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveNov 26, 2025Other filingsSEC
424B4 · ProspectusNov 25, 2025Offer documentSEC
CORRESP · Letter to the SECNov 24, 2025Other filingsSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
8-K · Current reportOct 30, 2025Material contractSEC
SCHEDULE 13G · Big-stake noticeOct 6, 2025Big-stake noticeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 3, 2025Insider tradeSEC
S-1 · Registration statementOct 1, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeSep 17, 2025Big-stake noticeSEC
8-K · Current reportSep 16, 2025Current reportSEC
8-K · Current reportSep 4, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 11, 2025Quarterly reportSEC
8-K · Current reportAug 11, 2025ResultsSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
4 · Change in ownershipAug 8, 2025Insider tradeSEC
424B4 · ProspectusAug 8, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 4, 2025Other filingsSEC
CORRESP · Letter to the SECJul 31, 2025Other filingsSEC
UPLOAD · Letter from the SECJul 30, 2025Other filingsSEC
S-1 · Registration statementJul 25, 2025Offer documentSEC
8-K · Current reportJul 24, 2025Meeting outcomeSEC
4 · Change in ownershipJul 21, 2025Insider tradeSEC
4 · Change in ownershipJul 21, 2025Insider tradeSEC
4 · Change in ownershipJul 21, 2025Insider tradeSEC
4 · Change in ownershipJul 21, 2025Insider tradeSEC
4 · Change in ownershipJul 21, 2025Insider tradeSEC
4 · Change in ownershipJul 21, 2025Insider tradeSEC
4 · Change in ownershipJul 21, 2025Insider tradeSEC
4 · Change in ownershipJul 21, 2025Insider tradeSEC
4 · Change in ownershipJul 21, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 9, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJul 8, 2025Big-stake noticeSEC
DEF 14A · Proxy statementJul 7, 2025Meeting noticeSEC
ARS · Annual report to shareholdersJul 3, 2025Annual reportSEC
8-K · Current reportJul 1, 2025Current reportSEC
8-K · Current reportJun 30, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeJun 25, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJun 25, 2025Big-stake noticeSEC
PRE 14A · Preliminary proxy statementJun 23, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeJun 23, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 23, 2025Big-stake noticeSEC
8-K · Current reportJun 23, 2025Current reportSEC
8-K · Current reportJun 20, 2025Current reportSEC
424B5 · ProspectusJun 20, 2025Offer documentSEC
8-K · Current reportJun 20, 2025Material contractSEC
424B4 · ProspectusJun 20, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 20, 2025Other filingsSEC
S-1MEF · Registration of more shares for the same offeringJun 18, 2025Offer documentSEC
8-K · Current reportJun 17, 2025Material contractSEC
CORRESP · Letter to the SECJun 16, 2025Other filingsSEC
S-1 · Registration statementJun 16, 2025Offer documentSEC
UPLOAD · Letter from the SECJun 4, 2025Other filingsSEC
DRS · Draft registration statementMay 30, 2025Offer documentSEC
424B3 · ProspectusMay 28, 2025Offer documentSEC
8-K · Current reportMay 23, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveMay 23, 2025Other filingsSEC
8-K · Current reportMay 22, 2025Current reportSEC
424B5 · ProspectusMay 22, 2025Offer documentSEC
CORRESP · Letter to the SECMay 21, 2025Other filingsSEC
UPLOAD · Letter from the SECMay 20, 2025Other filingsSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
S-1 · Registration statementMay 13, 2025Offer documentSEC
RW · Request to withdraw a registrationMay 13, 2025Other filingsSEC
RW · Request to withdraw a registrationMay 13, 2025Other filingsSEC
S-3 · Registration statementMay 2, 2025Offer documentSEC
8-K · Current reportApr 29, 2025Current reportSEC
424B5 · ProspectusApr 29, 2025Offer documentSEC
424B4 · ProspectusApr 28, 2025Offer documentSEC
8-K · Current reportApr 28, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeApr 25, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 25, 2025Big-stake noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 25, 2025Big-stake noticeSEC
8-K · Current reportApr 22, 2025Material contractSEC
424B4 · ProspectusApr 22, 2025Offer documentSEC
DApr 18, 2025Other filingsSEC
PRE 14A · Preliminary proxy statementApr 10, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeApr 10, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 9, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 8, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 7, 2025Big-stake noticeSEC
8-K · Current reportApr 4, 2025Material contractSEC
424B4 · ProspectusApr 4, 2025Offer documentSEC
S-1/A · Registration statement, amendedApr 1, 2025Offer documentSEC
S-1/A · Registration statement, amendedMar 27, 2025Offer documentSEC
S-1/A · Registration statement, amendedMar 27, 2025Offer documentSEC
S-1/A · Registration statement, amendedMar 25, 2025Offer documentSEC
8-K · Current reportMar 20, 2025Current reportSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
S-1 · Registration statementMar 3, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 27, 2025Other filingsSEC
CORRESP · Letter to the SECFeb 24, 2025Other filingsSEC
UPLOAD · Letter from the SECFeb 21, 2025Other filingsSEC
S-3 · Registration statementFeb 14, 2025Offer documentSEC
10-K · Annual reportFeb 14, 2025Annual reportSEC
8-K · Current reportFeb 14, 2025ResultsSEC
8-K · Current reportFeb 11, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 10, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 10, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveJan 3, 2025Other filingsSEC
CORRESP · Letter to the SECJan 2, 2025Other filingsSEC
UPLOAD · Letter from the SECDec 30, 2024Other filingsSEC
S-3 · Registration statementDec 20, 2024Offer documentSEC
8-K · Current reportDec 12, 2024Material contractSEC
8-K · Current reportDec 12, 2024Current reportSEC
8-K · Current reportDec 4, 2024Current reportSEC
8-K · Current reportDec 3, 2024Current reportSEC
8-K · Current reportNov 26, 2024Current reportSEC
8-K · Current reportNov 22, 2024Current reportSEC
8-K · Current reportNov 20, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC

This page holds 200 of 748 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Aptevo Therapeutics Inc.’s releases · as of Nov 16, 2026

Common shares
3,464,923
Fully diluted
3,464,923

Fully diluted

LineSharesAs of
Common shares3,464,923Nov 16, 2026

Warrants and options

Lot
Warrants · US$1.08 · expire about Nov 2031
Warrants · US$4.03 · expire about Aug 2031
Warrants · US$3.25 · expire about Jun 2030
Warrants · US$1.19 · expire about Apr 2030
Warrants · US$4.03 · expiry not stated
Warrants · US$1.08 · expiry not stated

Share count over time

CountShares
Nov 16, 20263,464,923

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Sabby Management, LLC233K6.7%US$423KSep 30, 2026
Hudson Bay Capital Management LP40,7001.2%US$74,074Sep 30, 2026
Citadel25,1710.73%US$45,811Sep 30, 2026
Gsa Capital Partners LLP21,5390.62%US$39,000Sep 30, 2026
Vanguard16,8550.49%US$30,676Sep 30, 2026
Tower Research Capital LLC (TRC)1,9110.06%US$3,478Sep 30, 2026
Osaic Holdings, Inc.3600.01%US$664Sep 30, 2026
SBI Securities Co., Ltd.105<0.01%US$191Sep 30, 2026
Caitong International Asset Management Co., Ltd3<0.01%US$5Sep 30, 2026
Danske Bank A/S1<0.01%US$2Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund12,7130.37%US$56,446Jun 30, 2026
Fidelity Extended Market Index Fund8,9010.26%US$43,704May 31, 2026
Fidelity Series Total Market Index Fund1,5480.04%US$7,601May 31, 2026

Big stakes

StakeStakeSharesDateFiling
NIOWAVE, INC.12.20%152KMay 25, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Anatolio B Cruz III
Other companies: Graf Acquisition Corp IV (Director · May 20, 2021 – May 20, 2021 · Past); Scripps Networks Interactive Inc (CLO & Corporate Secretary · Jul 1, 2008 – Aug 14, 2012 · Past); E.W. Scripps Company (The) (EVP & General Counsel · Feb 15, 2006 – Jul 1, 2008 · Past)
Director · Jul 15, 2016 – Jul 15, 2016 · Past
Marvin L. White
Other companies: Emergent BioSolutions Inc. (Independent Director · Since at least Jun 1, 2010); CoLucid Pharmaceuticals Inc (Director · Jul 9, 2015 – Mar 1, 2017 · Past); Washington Prime Group Inc (Director · May 8, 2014 – Aug 4, 2014 · Past)
Executive Chair · Since at least Jul 29, 2016
Daniel J. Abdun-Nabi
Other companies: Regenxbio Inc. (Director · Aug 5, 2016 – Jun 4, 2021 · Past); Emergent BioSolutions Inc. (CEO, Director · Nov 14, 2006 – Mar 4, 2019 · Past)
President · Since at least Aug 1, 2016
Jane A. Gross
Other companies: BriaCell Therapeutics Corp (Director of the Board · Since at least Aug 1, 2022); aTyr Pharma, Inc. (Director · Since at least Jun 28, 2019)
SVP & Chief Scientific Officer · Sep 1, 2016 – Jan 29, 2021 · Past
Dirk Huebner
Other companies: Mersana Therapeutics Inc (Chief Medical Officer · Nov 30, 2018 – Jan 15, 2020 · Past)
Senior Vice President and Chief Medical Officer · Since at least Jul 1, 2025
Fuad El-Hibri
Other companies: Emergent BioSolutions Inc. (Director · Nov 14, 2006 – Dec 3, 2021 · Past)
Director · Aug 1, 2016 – Dec 3, 2021 · Past
John E. Niederhuber
Other companies: Emergent BioSolutions Inc. (Director · Aug 23, 2010 – May 18, 2016 · Past)
Lead Independent Director · Since at least Aug 1, 2016
Randy Joe Maddux
Other companies: iBio, Inc. (Chief Operating Officer · Dec 1, 2020 – Dec 7, 2021 · Past)
SVP of Operations, CMO · Aug 23, 2016 – Jul 27, 2020 · Past
Robert Kramer
Other companies: Emergent BioSolutions Inc. (President and CEO, Director · May 31, 2013 – Jun 9, 2023 · Past)
President, Director · Jul 15, 2016 – Jul 15, 2016 · Past
Zsolt Harsanyi
Other companies: Emergent BioSolutions Inc. (Independent Director, Chairman of the Board · Since at least Nov 14, 2006)
Director · Since at least Jul 15, 2016
All 22 people
PersonSeat
Barbara Lopez KunzDirector · Since at least Aug 1, 2016
Daphne TaylorSVP, CFO · Since at least Mar 3, 2023
Eric M BurtDirector · Jul 15, 2016 – Jul 15, 2016 · Past
Grady Grant IIIDirector · Since at least Aug 1, 2016
Jeff LamothePresident and Chief Executive Officer · Since at least Aug 10, 2026
Jeffrey G LamothePresident and CEO, Director · Since at least Jul 29, 2016
Mary J. JanatpourSenior Vice President and Chief Scientific Officer · Since at least May 20, 2026
Michael AdelmanSVP, Commercial Operations · Nov 1, 2019 – Feb 18, 2020 · Past
Michael DarlingDirector · Jul 15, 2016 – Jul 15, 2016 · Past
Miriam Weber MillerVice President, Investor Relations and Corporate Communications · Since at least Oct 26, 2026
Scott C StromattChief Medical Officer and SVP · Jul 29, 2016 – Feb 28, 2019 · Past
SoYoung KwonSenior Vice President and General Counsel, Business Development and Corporate Affairs · Since at least May 24, 2021

Open People

Log in to ask 6ix AI your own questions about Aptevo Therapeutics Inc.